Form 4 for CGEM Cullinan Therapeutics, Inc.
Accepted 2023-01-06 00:00:00 ET · period of report 2022-12-30 · accession 0000899243-23-001157 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-06 | 2022-12-30 | CGEM | Trigilio Jeffrey | CFO | A - Grant | $8.97 | +201 | 41.4K | +0.5% | +$1,803 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-30 | A | A | 201 | $8.97 | 41,402 | D | — | — | (F1) The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c). (F2) In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on December 30, 2022. |